UCLA Department of Medicine - Hematology & Oncology
Welcome,         Profile    Billing    Logout  
 14 Trials 
69 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hecht, Joel R
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting
2/3
700
US
GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin
Gritstone bio, Inc.
Colorectal Neoplasms
03/27
03/27
NCT00047151: Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer

Active, not recruiting
2
US
panitumumab, fluorouracil, irinotecan hydrochloride, leucovorin calcium
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Colorectal Cancer
 
 
NCT05249101: A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma

Recruiting
1/2
70
US
Ivaltinostat, Capecitabine, Xeloda
CG Pharmaceuticals, Inc
Metastatic Pancreatic Adenocarcinoma
02/26
06/26
AFNT211-22-101, NCT06105021: Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects with Advanced or Metastatic Solid Tumor

Recruiting
1/2
100
US
AFNT-211
Affini-T Therapeutics, Inc.
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
12/25
12/29
NCT06218914: A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation

Recruiting
1
24
US
NT-112: Autologous, engineered T Cells targeting KRAS G12D
AstraZeneca
Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer, Solid Tumor, Adult, KRAS G12D
08/27
08/40
LYL845-101, NCT05573035: A Study to Investigate LYL845 in Adults With Solid Tumors

Active, not recruiting
1
108
US
LYL845
Lyell Immunopharma, Inc.
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
08/25
09/27
SGNEGFRd2-001, NCT05983133: A Study of SGN-EGFRd2 in Advanced Solid Tumors

Recruiting
1
275
Europe, US
SGN-EGFRd2
Seagen Inc.
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma
07/27
09/28
Sun, Li
NCT04908865: Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)

Active, not recruiting
4
67
RoW
Belimumab, Standard therapy
GlaxoSmithKline
Systemic Lupus Erythematosus
05/24
09/24
NCT05908695: An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

Recruiting
4
1312
RoW
GV-971, Placebo
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Alzheimer's Disease
06/29
12/29
HER2CLIMB-02, NCT03975647 / 2019-005017-39: A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Jan 2024 - Dec 2024: From HER2CLIMB-02 trial for breast cancer
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of HER2CLIMB-02 trial in combination with Kadcyla for breast cancer
Active, not recruiting
3
466
Europe, Canada, Japan, US, RoW
tucatinib, ONT-380, placebo, T-DM1, Kadcyla
Seagen Inc., Seagen Inc., Seattle Genetics, Inc., Seagen Inc
HER2-positive Breast Cancer
06/23
10/27
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
551
RoW
HTD1801, berberine ursodeoxycholate, Placebo
HighTide Biopharma Pty Ltd
Type 2 Diabetes Mellitus
03/25
12/25
NCT06145893: A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease

Recruiting
3
162
RoW
Hemay005, Mufemilast, Phosphodiesterase 4 (PDE4) inhibitors, Placebo
Ganzhou Hemay Pharmaceutical Co., Ltd
Behçet's Disease
11/24
03/25
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Active, not recruiting
3
274
RoW
BPI-16350, placebo, Fulvestrant
Betta Pharmaceuticals Co., Ltd.
Breast Cancer
12/23
07/25
SMART, NCT06722586: Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia

Recruiting
3
84
RoW
Sirolimus, Rapamycin, mTOR inhibitor, Placebo
Peking University First Hospital, North China Pharmaceutical Co.,Ltd
Antiphospholipid (aPL)-positive, Thrombocytopaenia
12/27
12/27
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
TQB2450-II-08, NCT04574284: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Recruiting
2
196
RoW
TQB2450, Anlotinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Endometrial Cancer
12/21
04/22
NCT04830644: A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.

Recruiting
2
144
RoW
Iguratimod, Placebo
Jiangsu Simcere Pharmaceutical Co., Ltd.
Primary Sjögren Syndrome
04/22
06/22
NCT06180889: Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Recruiting
2
240
RoW
Enoxaparin, KN060 Low, KN060 Middle, KN060 Hight
Suzhou Alphamab Co., Ltd.
Knee Arthroplasty, Total
12/25
04/26
NCT06250062: A Clinical Study of JS005 in Patients With Ankylosing Spondylitis

Recruiting
2
261
RoW
Recombinant humanized IL-17A Monoclonal Antibody（JS005）, Placebo（JS005）
Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH
Ankylosing Spondylitis
02/25
10/25
NCT06173037: RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Recruiting
2
88
RoW
RC88, RC88 for Injection
RemeGen Co., Ltd.
Primary Peritoneal Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer
06/26
12/26
NCT06241781: Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

Recruiting
2
64
RoW
GT101 injection, Gemcitabine injection
Grit Biotechnology
Adult
01/27
01/27
NCT06315231: Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients

Recruiting
2
200
RoW
Edaravone dexborneol sublingual tablet, Placebo
Simcere Pharmaceutical Co., Ltd
Post-stroke Cognitive Impairment
12/26
12/26
NCT06251947: Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen

Recruiting
2
83
RoW
Efbemalenograstim Alfa
Shandong University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Ovarian Cancer, Cervical Cancer
06/26
12/26
PALIZADE, NCT05781750: A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis

Suspended
2
279
Europe, US, RoW
zetomipzomib, KZR-616, placebo, matching placebo
Kezar Life Sciences, Inc.
Lupus Nephritis
05/26
07/26
TQB2858-Ⅰ-06, NCT05068921: A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy

Recruiting
1
40
RoW
TQB2858 injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Cervical Cancer
05/23
07/23
NCT06420154: The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases

Not yet recruiting
1
9
RoW
anti-CD19-CAR-T cells
First Affiliated Hospital of Wenzhou Medical University, Shanghai First Song Therapeutics Co., Ltd
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy, ANCA Associated Vasculitis, Antiphospholipid Syndrome
05/27
05/27
BAT-8006-001-CR, NCT05378737: Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection

Recruiting
1
216
RoW
BAT8006 for Injection, Exatecan conjugate of recombinant humanized monoclonal antibody against folate receptor α for injection
Bio-Thera Solutions
Advanced Solid Tumors
12/24
12/25
NCT05925452: To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.

Recruiting
N/A
221
RoW
GenaKumab
Changchun GeneScience Pharmaceutical Co., Ltd.
Active Systemic Juvenile Idiopathic Arthritis
03/28
06/28
NCT03647852: Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura

Recruiting
N/A
150
RoW
Methylprednisolone, IVIG, other basic supportive treatment
Children's Hospital of Fudan University, Shanghai Children's Hospital, Shanghai Children's Medical Center
Henoch-Schönlein Purpura
10/24
10/25
NCT04532541: Monogenic Lupus in Childhood Onset Systemic Lupus Erythematosus

Recruiting
N/A
200
RoW
Monogenic lupus screening
Children's Hospital of Fudan University
Monogenic Lupus, Systemic Lupus Erythematosus
09/25
09/25
COAST, NCT03653156: China Cognition and Aging Study

Recruiting
N/A
100000
RoW
Capital Medical University, Beijing Tiantan Hospital, Beijing Chao Yang Hospital, Fu Xing Hospital, Capital Medical University, Peking Union Medical College Hospital, Peking University First Hospital, Peking University Third Hospital, Chinese PLA General Hospital, China-Japan Friendship Hospital, Beijing Geriatric Hospital, The First Affiliated Hospital of Dalian Medical University, Fujian Medical University Union Hospital, Guangzhou Psychiatric Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital Of Guizhou Medical University, Handan Central Hospital, Hebei General Hospital, First Hospital of Shijiazhuang City, Tangshan Worker's Hospital, Hunan Provincial People's Hospital, Kaifeng Central Hospital, People's Hospital of Zhengzhou University, Wuhan University Zhongnan Hospital, First Affiliated Hospital of Harbin Medical University, Tongji Hospital, People's Hospital Affiliated Hubei Medical University, The Third Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The First Hospital of Jilin University, China-Japan Union Hospital, Jilin University, Subei People's Hospital of Jiangsu, Nantong University Affiliated Hospital, Mineral General Hospital, Xuzhou, Jiangxi Provincial People's Hopital, Anshan Central Hospital, The Affiliated Zhongshan Hospital of Dalian University, First Hospital of China Medical University, Baotou Central Hospital, General Hospital of Ningxia Medical University, The People's Hospital of Ningxia, The Affiliated Hospital of Qingdao University, The 960th Hospital of PLA, Qilu Hospital of Shandong University, Qilu Hospital of Shandong University (Qingdao), Shandong Provincial Hospital, Qingdao Municipal Hospital, The First Affiliated Hospital of Shanxi Medical University, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, RenJi Hospital, Shanghai Changzheng Hospital, Affiliated Hospital of North Sichuan Medical College, Tianjin Huanhu Hospital, Tianjin Medical University General Hospital, Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region, Ningbo Medical Center Lihuili Hospital, First Affiliated Hospital of Wenzhou Medical University, First Affiliated Hospital of Zhejiang University, Shao Yifu Hospital of Zhejiang Medical University, Zhejiang Provincial People's Hospital, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, The Second Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Anhui Medical University, People's Hospital of Chongqing, Dongfang Hospital Beijing University of Chinese Medicine, Zigong No.1 Peoples Hospital
Mild Cognitive Impairment(MCI), Alzheimer Disease, Late Onset, Familial Alzheimer Disease (FAD), Vascular Dementia (VaD), Normal Control, Non-Alzheimer Degenerative Dementia
01/38
01/38
CFAN, NCT03657732: The Chinese Familial Alzheimer's Network

Recruiting
N/A
40000
RoW
Capital Medical University, Beijing Tiantan Hospital, Beijing Chao Yang Hospital, Fu Xing Hospital, Capital Medical University, Peking Union Medical College Hospital, Peking University First Hospital, Peking University Third Hospital, Chinese PLA General Hospital, China-Japan Friendship Hospital, Beijing Geriatric Hospital, The First Affiliated Hospital of Dalian Medical University, Fujian Medical University Union Hospital, Guangzhou Psychiatric Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital Of Guizhou Medical University, Handan Central Hospital, Hebei General Hospital, First Hospital of Shijiazhuang City, Tangshan Worker's Hospital, Henan Provincial People's Hospital, Kaifeng Central Hospital, People's Hospital of Zhengzhou University, First Affiliated Hospital of Harbin Medical University, Tongji Hospital, People's Hospital Affiliated Hubei Medical University, Wuhan University Zhongnan Hospital, The Third Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The First Hospital of Jilin University, China-Japan Union Hospital, Jilin University, Subei People's Hospital of Jiangsu, Nantong University Affiliated Hospital, Mineral General Hospital, Xuzhou, Jiangxi Provincial People's Hopital, Anshan Central Hospital, The Affiliated Zhongshan Hospital of Dalian University, First Hospital of China Medical University, Baotou Central Hospital, General Hospital of Ningxia Medical University, The People's Hospital of Ningxia, The Affiliated Hospital of Qingdao University, The 960th Hospital of PLA, Qilu Hospital of Shandong University, Qilu Hospital of Shandong University (Qingdao), Shandong Provincial Hospital, Qingdao Municipal Hospital, The First Affiliated Hospital of Shanxi Medical University, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, RenJi Hospital, Shanghai Changzheng Hospital, Affiliated Hospital of North Sichuan Medical College, Tianjin Huanhu Hospital, Tianjin Medical University General Hospital, Traditional Chinese Medicine Hospital of Xinjiang Autonomous Region, Ningbo Medical Center Lihuili Hospital, First Affiliated Hospital of Wenzhou Medical University, First Affiliated Hospital of Zhejiang University, Shao Yifu Hospital of Zhejiang Medical University, Zhejiang Provincial People's Hospital, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, The Second Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Anhui Medical University, People's Hospital of Chongqing, Dongfang Hospital Beijing University of Chinese Medicine, Zigong No.1 Peoples Hospital
Alzheimer Disease, Familial Alzheimer Disease (FAD)
01/38
01/38
Yan, Xue
HER2CLIMB-02, NCT03975647 / 2019-005017-39: A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Jan 2024 - Dec 2024: From HER2CLIMB-02 trial for breast cancer
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of HER2CLIMB-02 trial in combination with Kadcyla for breast cancer
Active, not recruiting
3
466
Europe, Canada, Japan, US, RoW
tucatinib, ONT-380, placebo, T-DM1, Kadcyla
Seagen Inc., Seagen Inc., Seattle Genetics, Inc., Seagen Inc
HER2-positive Breast Cancer
06/23
10/27
Dayyani, Farshid
A022102, NCT05677490: MFOLFIRINOX Versus MFOLFOX with or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Recruiting
3
382
US
Fluorouracil, 2,4-Dioxo-5-fluoropyrimidine, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluoro-2,4(1H,3H)-pyrimidinedione,, Leucovorin Calcium, 1492-18-8, 5-Formyl Tetrahydrofolate, Calcium (6S)-Folinate, Calcium Folinate, Oxaliplatin, 1-OHP, Dacotin, Dacplat, ELOXATIN, Irinotecan, Nivolumab, MDX-1106, Opdivo, Magnetic Resonance Imaging, MRI, Computed Tomography, CAT Scan, Computed Axial Tomography, CT Scan, Biospecimen Collection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC V8, Clinical Stage III Gastric Cancer AJCC V8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC V8, Clinical Stage IV Esophageal Adenocarcinoma AJCC V8, Clinical Stage IV Gastric Cancer AJCC V8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC V8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
11/28
11/28
NCT04164979: Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma

Active, not recruiting
2
20
US
Cabozantinib, CABOMETYX, COMETRIQ, Pembrolizumab, KEYTRUDA
University of California, Irvine, Exelixis
Gastric Adenocarcinoma, GastroEsophageal Cancer
11/23
12/24
NCT04579679 / 2020-006118-19: Open-Label Surufatinib in European Patients With NET

Active, not recruiting
2
78
Europe, US
Surufatinib, HMPL-012, sulfatinib
Hutchmed
Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET
09/24
09/24
NCT04472767: Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

Recruiting
2
35
US
Nivolumab, OPDIVO®, Ipilimumab, YERVOY®, Cabozantinib, CABOMETYX®, COMETRIQ, Transarterial Chemoembolization, TACE
University of California, Irvine, Exelixis
Hepatocellular Carcinoma, HCC
06/26
09/27
ETCTN 10476, NCT04941287: Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Active, not recruiting
2
56
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cobimetinib, Cotellic, GDC 0973, GDC-0973, GDC0973, MEK Inhibitor GDC-0973, XL 518, XL-518, XL518, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Varlilumab, CDX 1127, CDX-1127, CDX1127, Immunoglobulin G1, Anti-(Human CD Antigen CD27) (Human Monoclonal CDX-1127 Clone 1f5 Heavy Chain), Disulfide with Human Monoclonal CDX-1127 Clone 1f5 Kappa-chain, Dimer
National Cancer Institute (NCI)
Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Recurrent Distal Bile Duct Adenocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Liver Carcinoma
01/24
07/25
NCT05724108: Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Recruiting
2
94
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Lutetium Lu 177 Dotatate, 177 Lu-DOTA-TATE, 177 Lu-DOTA-Tyr3-Octreotate, 177Lu-DOTA0-Tyr3-Octreotate, Lutathera, Lutetium (177Lu) Oxodotreotide, Lutetium Lu 177 DOTA(0)-Tyr(3)-Octreotate, Lutetium Lu 177-DOTA-Tyr3-Octreotate, lutetium Lu 177-DOTATATE, Lutetium Oxodotreotide Lu-177, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Triapine, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, 3-AP, 3-Apct, OCX-0191, OCX-191, OCX191, PAN-811
National Cancer Institute (NCI)
Metastatic Neuroendocrine Tumor
03/25
03/25
DisTinGuish, NCT04363801: A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Hourglass Oct 2023 - Mar 2024 : Q4'23/Q1'24 - Initial ORR data from DisTinGuish trial for 2L gastric cancer
Oct 2023 - Dec 2023: Initial data from part C of DisTinGuish trial in combination with tislelizumab for 1L gastric cancer
Checkmark Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Nov 2022 - Nov 2022: Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Checkmark ORR, PFS and OS data from DisTinGuish trial in combination with tislelizumab for gastroesophageal junction cancer or gastric cancer
More
Active, not recruiting
2
232
Europe, US, RoW
DKN-01 300mg, DKN-01 600mg, DKN-01 400mg, Tislelizumab 200mg, Tislelizumab 400mg, Oxaliplatin, Capecitabine 1000mg/ m2 BID, Xeloda, Leucovorin Calcium, Folinic acid, Fluorouracil
Leap Therapeutics, Inc., BeiGene
Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer
06/25
12/25
NCT05117931: A Study of Amivantamab in People with Esophagogastric Cancer

Recruiting
2
25
US
Amivantamab
Memorial Sloan Kettering Cancer Center, Janssen Pharmaceuticals
Esophagogastric Cancer
11/25
11/25
MRG002-101, NCT04492488: A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Active, not recruiting
1/2
129
US
MRG002
Shanghai Miracogen Inc.
Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer
10/22
12/24
NCT04068194: Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Recruiting
1/2
103
US
Avelumab, Bavencio, MSB 0010718C, MSB-0010718C, MSB0010718C, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Hypofractionated Radiation Therapy, Hypofractionated, Hypofractionated Radiotherapy, hypofractionation, Radiation, Hypofractionated, Peposertib, 3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)-, M 3814, M-3814, M3814, MSC 2490484A, MSC-2490484A, MSC2490484A, Nedisertib
National Cancer Institute (NCI)
Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Carcinoma, Locally Advanced Unresectable Malignant Solid Neoplasm, Metastatic Cholangiocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Malignant Solid Neoplasm, Stage III Gallbladder Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Unresectable Malignant Solid Neoplasm
12/25
12/25
NCT06157892: A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Recruiting
1/2
198
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, tucatinib, TUKYSA, ONT-380, ARRY-380
Seagen Inc., RemeGen Co., Ltd.
Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
01/30
01/30
ETCTN 10366, NCT04172532: Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Recruiting
1/2
98
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Hypofractionated Radiation Therapy, Hypofractionated, Hypofractionated Radiotherapy, hypofractionation, Radiation, Hypofractionated, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Peposertib, 3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)-, M 3814, M-3814, M3814, MSC 2490484A, MSC-2490484A, MSC2490484A, Nedisertib, Placebo Administration
National Cancer Institute (NCI)
Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
08/26
08/26
NCT05630937 / 2020-001002-26: Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy

Completed
1/2
31
Europe, US
NMS-01940153E
Nerviano Medical Sciences
Unresectable Hepatocellular Carcinoma (HCC)
01/24
08/24
NCT04074343: TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

Completed
1
20
US
TAS-102, LONSURF, trifluoridine and tipiracil, Irinotecan, CAMPTOSAR, CPT-11
University of California, Irvine, Taiho Pharmaceutical Co., Ltd.
Gastric Adenocarcinoma, GastroEsophageal Cancer
07/21
07/22
NCT04868773: Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

Active, not recruiting
1
12
US
Cabozantinib, CABOMETYX®, COMETRIQ, TAS-102, trifluridine and tipiracil
University of California, Irvine
Colorectal Cancer, Colorectal Carcinoma, Metastatic Cancer, CRC
08/23
02/25
NCT04920032: Study of CtDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Recruiting
1
22
US
TAS-102, LONSURF, trifluoridine and tipiracil, Irinotecan, CAMPTOSAR, CPT-11, Standard Treatment, Signatera MRD ctDNA Assay
University of California, Irvine, Taiho Pharmaceutical Co., Ltd., Natera, Inc.
Colon Adenocarcinoma, Colorectal Cancer
12/24
12/25
ETCTN 10402, NCT04514497: Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Active, not recruiting
1
96
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Elimusertib, ATR Inhibitor BAY1895344, ATR Kinase Inhibitor BAY1895344, BAY 1895344, BAY-1895344, BAY1895344, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, CPT11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U 101440E, U-101440E, U101440E, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Topotecan Hydrochloride, Evotopin, Hycamptamine, Hycamtin, Nogitecan Hydrochloride, Potactasol, SKF S 104864 A, SKF S-104864-A, SKF S104864A, Topotec, Topotecan HCl, topotecan hydrochloride (oral)
National Cancer Institute (NCI)
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Lung Small Cell Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Neuroendocrine Carcinoma, Unresectable Pancreatic Adenocarcinoma
02/25
02/25
NCI-2022-04099, NCT05372614: Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Suspended
1
30
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Neratinib Maleate, 2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-, (2Z)-2-butenedioate (1:1), HKI-272 Maleate, NERATINIB MALEATE ANHYDROUS, Nerlynx, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, T-DXd, WHO 10516
National Cancer Institute (NCI)
Malignant Solid Neoplasm
06/25
06/25
NCT05685602: CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Recruiting
1
36
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Emavusertib, AU 4948, AU-4948, CA 4948, CA-4948, CA4948, Interleukin-1 Receptor-associated Kinase 4 Inhibitor CA-4948, IRAK4 Inhibitor CA-4948, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nab-paclitaxel, ABI 007, ABI-007, ABI007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Naveruclif, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Paclitaxel Nanoparticle Albumin-bound, Paclitaxel Protein-Bound, Protein-bound Paclitaxel, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
03/25
03/25
NCT03863145: Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors

Recruiting
1
90
US
CB-03-10
Cosmo Technologies Ltd
Advanced Refractory Solid Tumors, Subjects Considered Likely to Respond to CB-03-10
01/26
06/26
RANT-GC, NCT05733689: Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers ( Trial)

Not yet recruiting
1
20
US
ctDNA Blood Test, FLOT, FOLFOX, FOLFIRI, FOLFIRINOX, PACLITAXEL with or without CARBOPLATIN, DOCETAXEL and IRINOTECAN (alone or combined), NIVOLUMAB (alone or when added to a regimen above), PEMBROLIZUMAB (alone or when added to a regimen above)
University of California, Irvine, Natera, Inc.
Gastroesophageal Adenocarcinoma
02/26
02/26
DASH, NCT04704661: Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The Trial

Recruiting
1
51
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Ceralasertib, AZD6738, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, T-DXd, WHO 10516
National Cancer Institute (NCI)
Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Salivary Gland Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Breast Carcinoma, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Salivary Gland Carcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Salivary Gland Carcinoma
03/26
03/26
McAndrew, Nicholas
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
TRIO-US B-12 TALENT, NCT04553770: Trastuzumab Deruxtecan Alone or in Combination with Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Checkmark Presentation of data from TALENT trial for HER2 Low, HR+ breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from TALENT trial for HER2 Low, HR+ breast cancer at SABCS 2022
Recruiting
2
88
US
Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, WHO 10516
Jonsson Comprehensive Cancer Center, Translational Research in Oncology-U.S, Daiichi Sankyo Co., Ltd.
Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
09/25
09/25
UCLA B-13, NCT05319873: Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Recruiting
1/2
18
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238, Pertuzumab, 2C4, 2C4 Antibody, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, Quality-of-Life Assessment, Quality of Life Assessment, Ribociclib, Kisqali, LEE-011, LEE011, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera, Tucatinib, ARRY-380, Irbinitinib, ONT-380, Tukysa
Jonsson Comprehensive Cancer Center, Seagen Inc., Novartis
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced HER2-Positive Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
04/25
04/26
NCT05377996: A Study of XMT-1660 in Participants With Solid Tumors

Hourglass Jul 2024 - Dec 2024 : Initial dose escalation and backfill cohort data for solid tumors
Recruiting
1
319
US
XMT-1660
Mersana Therapeutics
Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
12/26
05/27
Tao, Weiping
HER2CLIMB-02, NCT03975647 / 2019-005017-39: A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Jan 2024 - Dec 2024: From HER2CLIMB-02 trial for breast cancer
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of HER2CLIMB-02 trial in combination with Kadcyla for breast cancer
Active, not recruiting
3
466
Europe, Canada, Japan, US, RoW
tucatinib, ONT-380, placebo, T-DM1, Kadcyla
Seagen Inc., Seagen Inc., Seattle Genetics, Inc., Seagen Inc
HER2-positive Breast Cancer
06/23
10/27
LEONARDA-1, NCT05054751: GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Completed
3
275
RoW
GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant
Genor Biopharma Co., Ltd.
Locally Advanced or Metastatic Breast Cancer
12/22
03/24
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Recruiting
3
350
RoW
GB491 combined with Letrozole, Placebo combined with Letrozole
Genor Biopharma Co., Ltd.
Breast Cancer
01/26
01/27
NCT04600947: Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

Not yet recruiting
2
69
RoW
LP002
Taizhou HoudeAoke Biomedical Co., Ltd.
Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
05/22
05/23
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

Recruiting
2
185
RoW
HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor
Hutchison Medipharma Limited
Marginal Zone Lymphoma, Follicular Lymphoma
04/24
12/24
NCT05033132: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer

Withdrawn
2
177
RoW
Balstilimab, Balstilimab + Zalifrelimab
Agenus Inc., Betta Pharmaceuticals Co., Ltd.
Cervical Cancer
12/24
12/24
Davis, Jenna L
NCT06157892: A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Recruiting
1/2
198
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, tucatinib, TUKYSA, ONT-380, ARRY-380
Seagen Inc., RemeGen Co., Ltd.
Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
01/30
01/30
NCT06445062: Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors

Recruiting
1/2
1130
US
RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine, nab-paclitaxel, RMC-9805
Revolution Medicines, Inc.
Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
05/27
07/27
NCT04294160: A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Terminated
1
122
Europe, Canada, US, RoW
Dabrafenib, DRB436, Tafinlar, LTT462, Trametinib, TMT212, Mekinist, LXH254, TNO155, Spartalizumab, PDR001, Tislelizumab, VDT482, BGBA317
Novartis Pharmaceuticals
BRAF V600 Colorectal Cancer
09/24
09/24
Klipfel, Molly
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27

Download Options